Pulmonary Carcinogenicity of Inhaled Particles and the Maximum Tolerated Dose

G. Oberdörster

Department of Environmental Medicine, University of Rochester, Rochester, New York

Chronic inhalation bioassays in rodents are used to assess pulmonary carcinogenicity for purposes of hazard identification and potentially for risk characterization. The influence of high experimental doses on tumor development has been recognized for some time and has led to the concept of maximum tolerated dose (MTD) for dose selection, with the highest dose being at the MTD. Exposure at the MTD should ensure that the animals are sufficiently challenged while at the same time the animal's normal longevity is not altered from effects other than carcinogenicity. A characteristic of exposure–dose–response relationships for chronically inhaled particles is that lung tumors are significantly increased only at high exposure levels, and that lung tumors are seen in rats only but not in mice or hamsters. This lung tumor response in rats is thought to be secondary to persistent alveolar inflammation, indicating that the MTD may have been exceeded. Thus, mechanisms of toxicity and carcinogenicity may be dose dependent and may not operate at lower doses that humans normally experience. Despite awareness of this problem, carcinogenicity bioassays that evaluate particulate compounds in rodents have not always been designed with the MTD concept in mind. This is due to several problems associated with determining an appropriate MTD for particle inhalation studies. One requirement for the MTD is that some toxicity should be observed. However, it is difficult to define what degree of toxic response is indicative of the MTD. For particle inhalation studies, various noncancer end points in addition to mortality and body weight gain have been considered as indicators of the MTD, i.e., pulmonary inflammation, increased epithelial cell proliferation, increased lung weight, impairment of particle clearance function, and significant histopathological findings at the end of a subchronic study. However, there is no general agreement about quantification of these end points to define the MTD. To determine whether pulmonary responses are indicative of the MTD, we suggest defining an MTD based on results of a multidose subchronic and chronic inhalation study with a known human particulate carcinogen, e.g., asbestos or crystalline silica. Quantification of effects in such a study using the noncancer end points listed above would identify a dose level without significant signs of toxicity at the end of the subchronic study. If this dose level still results in significant lung tumor incidence at the end of the chronic study. We will have a sound basis for characterizing the MTD and justifying its use in future particle inhalation studies. Also, a better understanding of cellular and molecular mechanisms of particle-induced lung tumors is needed to support the MTD concept. — Environ Health Perspect 105(Suppl 5):1347–1356 (1997)

Key words: nonfibrous particles, fibers, lung tumor, rodent, bioassay, inhalation, dose–response

Introduction

The rodent carcinogenicity assays generally involve dosing animals over a 2-year period. Historically, high dose levels have often been selected which could induce significant toxicity or even mortality from causes other than cancer. This problem has been recognized for some time, and guidelines were proposed to limit the highest dose in such assays to the maximum tolerated dose (MTD) (1). These guidelines were based mainly on results from the oral exposure route, and although the same principles apply to other routes of animal dosing, there are specific differences that must be considered when applying the concept of the MTD to chronic particle inhalation studies. In this brief review of the pulmonary carcinogenicity observed in particle inhalation studies with rodents and the underlying potential mechanistic events, we identify respective problems with the current MTD definition. We conclude with a suggestion for defining the MTD for particle inhalation studies.

Particle Inhalation Studies and High-dose Effects

Table 1 lists several nonfibrous and fibrous particles which were used in chronic inhalation studies in rats and which induced lung tumors in this species. This list includes particles of low cytotoxicity such as carbon black, talc, and TiO₂, as well as cytotoxic particles such as quartz and various types of asbestos. All of these particles are poorly or only moderately soluble in the lung. Although it is conceivable that mechanisms of lung tumor induction in rats differ between fibrous and nonfibrous particles, the studies with particles listed in Table 1 were performed with inhaled concentrations (up to 250 mg/m³) much higher than those to which humans are exposed. One reason for using high exposures in these studies is to assure that the animals are adequately dosed so that during the short lifespan of a rat—compared to humans—the detection of potential carcinogenic effects is maximized. In the case of TiO₂, a difference between

| Table 1. Chronic particle inhalation studies in rats that resulted in induction of lung tumors |
|---------------------------------------------------------------|
| Nonfibrous | Fibrous |
| Antimony trioxide | Amsite |
| Carbon black | Anthophyllite |
| Coal dust | Chrysotile |
| Diesel soot | Crocidolite |
| Nickel oxide | Palgorskite |
| Nickel subsulfide | Potassium titanate |
| Oil shale | Refractory ceramic fiber |
| Quartz | Silicon carbide |
| Talc | Tremolite |

(pigment grade, ultrafine) Volcanic fly ash

Data from Morrow et al. (37) and Oberdörster (7).
ultrafine TiO\textsubscript{2} particles (particle diameter ~20 nm) and pigment grade TiO\textsubscript{2} (particle diameter 200–300 nm) should be noted: An inhaled mass concentration more than an order of magnitude lower and respectively lower gravimetric lung burdens of the ultrafine particles compared to the larger sized TiO\textsubscript{2} resulted in similar lung tumor incidence (2,3). This result is of interest, as it suggests that the term dose should not be used narrowly as a gravimetric lung burden only, and that other particle parameters can be more appropriate dose metrics as discussed below.

Based on the available data, our current knowledge of particle-induced lung tumors in rats can be summarized by stating that all inhaled particles—fibrous and nonfibrous—are likely to induce lung tumors in rats provided the particles are a) inhaled chronically at high concentrations, b) rat respirable, and c) of low in vivo solubility. The retained lung burden leading to induction of lung tumors can differ, depending on particle cytotoxicity, particle size, and particle shape, but is greater than 1 mg/g of lung for low toxicity particles. Although some of the particles listed in Table 1 have been characterized as confirmed human lung carcinogens, i.e., nickel sulfide, quartz, and various forms of asbestos (4,5), others were not found to be associated with an increase in lung tumors in exposed workers. Thus, the results of the rat studies raise the question as to whether these particles should be labeled as possible or even as probable human carcinogens. Underlying this problem is the fundamental question about the relevancy of the rat as an experimental animal for extrapolation of results of particle inhalation studies to humans, as the tumorigenic effect may be due to mechanisms that are only operative in the rat or operative only at high doses, which are not achieved in human lungs. The next section addresses these questions.

**Exposure–Dose–Response Relationships in Rats**

Multidose chronic inhalation studies in rats, using poorly soluble particles of low cytotoxicity, typically induced lung tumors at high concentrations only. Respective lung burdens were at a level characterized as particle overload of alveolar macrophages (AM), such that their physiological clearance function was severely impaired or had ceased completely (6). Chronic alveolar inflammation occurred as well. The presence of impaired AM-mediated particle clearance and chronic inflammation did not always result in a tumorigenic response in the rat studies, i.e., if these effects were only moderate. However, lung tumors were never found in rats when particle overload induced impaired clearance, and pulmonary inflammation were absent during chronic inhalation of particles (7). Respective dose–response relationships are consistent with a threshold dose above which lung tumors could be induced by a mechanism that may not be operative at lower doses.

Figure 1 depicts the result of the 2-year inhalation study in rats with pigment grade TiO\textsubscript{2} (particle size 200–300 nm) at exposure concentrations of 10, 50, and 250 mg/m\textsuperscript{3} (2). For purposes of comparison with ultrafine TiO\textsubscript{2} (particle size ~20 nm) reported in another study (3), the exposure term in Figure 1 is expressed as exposure concentration × duration (g/m\textsuperscript{3} × hr). For pigment grade TiO\textsubscript{2}, lung tumor incidence was increased only at the highest concentration, with a lung burden of 665 mg per rat lung. The realization that this result in the rat is secondary to toxicity based on lung particle overload led the U.S. Environmental Protection Agency (U.S. EPA) to remove TiO\textsubscript{2} from its toxic release inventory (8). Since other rodent species do not show this response, the appropriateness of using the rat model in a cancer bioassay with inhaled particles was questioned. Doubts about human extrapolation from rat studies were reinforced by findings of high particulate lung burdens in coal miners [up to 40 mg/g lung (9)] that did not lead to an increased risk of lung cancer in this group of heavily exposed humans (5). However, rats exposed to 200 mg/m\textsuperscript{3} coal dust (Table 1) developed lung tumors, although the number of animals in the study was low (10).

Thus, it seems to be firmly established that rats respond with lung tumor induction at chronic high exposures to poorly soluble particles of low toxicity, which results in the retention of high lung doses. However, even low exposure concentrations to such particles can induce lung tumors in rats. As mentioned before and shown in Figure 1, a 2-year inhalation study by Heinrich et al. (3) showed that ultrafine TiO\textsubscript{2} can increase lung tumor incidence in rats at much lower exposures and respective lower gravimetric lung burdens than were observed with larger sized pigment grade TiO\textsubscript{2} in the study by Lee et al. (2). TiO\textsubscript{2} lung burdens were 665 mg (pigment grade TiO\textsubscript{2}) and 39 mg (ultrafine TiO\textsubscript{2}). The different particle sizes of TiO\textsubscript{2} in the two studies can explain their differing biological activities, as demonstrated in a subchronic inhalation study in rats comparing pulmonary effects of pigment grade TiO\textsubscript{2} and ultrafine TiO\textsubscript{2} (11,12). In this study, pulmonary inflammatory response and impairment of AM-mediated clearance correlated best with the surface area rather than the mass of the retained particles. Further, a dosimetric evaluation of particle-induced carcinogenic responses in the rat revealed that particle surface area rather than mass, volume, or number of the retained particles correlated best with lung tumor incidence (13). To use the appropriate dose parameter is therefore crucial, and particle surface area appears to be the best descriptor. The concept that the surface area is a more relevant dose parameter than the mass of poorly soluble particles is very plausible as it is the surface of an insoluble particle which interacts with cellular and subcellular structures to elicit biological responses.

Most recently, Driscoll (14) reinforced the surface area concept when he compared the rat lung tumor response in a number of particle inhalation studies with the mass or surface area of the retained particles. Only the surface area showed a highly significant correlation, as demonstrated in Figure 2. The ultrafine TiO\textsubscript{2} dose retained in rat lungs in the study by Heinrich et al. (3), expressed as particle surface area, is in the range of the high dose of pigment grade TiO\textsubscript{2} in the study by Lee et al. (2). Figure 2 demonstrates again that particle-induced lung tumors in rats are a phenomenon of high doses (dose expressed as particle surface area) and that a threshold may exist below which the retained dose of particle surface area is too low to induce tumors. Because the ratio of particle surface area to particle mass can differ greatly among

---

**Figure 1.** Exposure–response relationship of lung tumor incidence in rats after 2-year exposure to pigment grade TiO\textsubscript{2} particles (2), demonstrating a nonlinear response. Also shown is the result of a 2-year exposure to ultrafine TiO\textsubscript{2} particles (3).
different types of poorly soluble particles of low toxicity, a high retained mass burden in the lung, although it may qualify as particle overload, is not necessarily associated with induction of lung tumors in rats. This is evidenced by the mid-dose of TiO₂ in the study of Lee et al. (2). The retained particle surface area is still low despite a high mass of 124 mg per rat lung.

We can infer from these arguments that particle mass is not the best dose parameter for particle-induced adverse pulmonary effects. Given this inference, the human data of high mass burdens in coal miners’ lungs have to be viewed in a different light. If the dose concept of particle surface area is applicable to other species, including humans, then retained mass burdens of 40 mg/g human lung (as reported for coal miners [see above]) of a particulate compound with low surface area will translate into a low dose expressed as surface area. Thus, coal miners need not reach a critical dose in their lungs to be at an increased risk for lung cancer. Unfortunately, no data are available to convert reported mass burdens of inhaled and retained coal particles in coal miners’ lungs to respective surface areas. However, data from Seixas et al. (15) and Burkhartt et al. (16) suggest that the surface area of coal dust is not very high because of the rather coarse particle sizes of airborne coal mine dust, with means of the size distribution ranging from 5 to 10 μm. Thus, we have to be cautious in dismissing the rat as being an inappropriate model for human extrapolation unless we have more compelling evidence that specific mechanisms of tumor induction by particles operate in the rat only. It is clear, however, that poorly soluble particles of low cytotoxicity induce lung tumors in the rat only at high lung burdens.

In contrast to the rat, lung tumors have not been observed in mice and hamsters after chronic high-level exposures to nonfibrinous particles of low solubility. Resistance to lung tumor induction in these two rodent species was evident in lung burdens of particles (i.e., talc, carbon black, diesel soot) that were as high as those in the rat studies, which resulted also in impaired clearance function of AM in mice and hamsters [reviewed by Oberdörster (7)]. However, the pulmonary inflammatory response elicited by particles was less pronounced in mice and hamsters, suggesting significant species differences in this response. With respect to inhaled fibrous particles, the hamster appears to be more likely to respond with mesothelioma than the rat but does not respond with lung tumors (17); the only chronic inhalation study in mice with fibers [chrysotile (18)] found that both lung tumors and mesotheliomas were induced.

In conclusion, lung tumor induction by inhalation of poorly soluble particles of low cytotoxicity (which showed negative results in genotoxicity assays) is highly species specific and only occurs at high dose levels. This may imply that a secondary mechanism of genotoxicity plays a role and that consequently certain defense mechanisms are better developed in one species compared to others and provide protection. Because the rat appears to be most sensitive with respect to lung tumor induction by high doses of inhaled particles, a discussion of mechanisms that are likely to be operative in this species at these high doses will be useful for an evaluation of the MTD and of the relevance of the rat model for humans.

**Mechanism of Particle-induced Lung Tumors in Rats**

Our present understanding of the cascade of events occurring in the rat lung during particle exposure is summarized in Figure 3. During chronic exposure to high concentrations of inhaled particles, phagocytosis by AM of particles deposited in the alveolar region results in AM activation, with release of a number of mediators including cytokines and chemokines. These mediators effect the recruitment of additional inflammatory cells, neutrophils (PMN), and macrophages, whose activation amplifies the existing inflammatory process through the release of additional inflammatory cytokines, growth factors, and reactive O₂⁻ and N-species (19,20). The mitogenic activity of growth factors on epithelial target cells (e.g., type II cells) leads to an increase in their proliferation rate. In addition, an increase in target cell mutation rates via the action of reactive species (O₂⁻-derived, N-derived, lipid peroxidation products) may occur, representing a secondary mechanism of particle-induced genotoxicity, with chronic alveolar inflammation playing a central role.

The inflammatory mechanism of particle-induced genotoxicity leading to lung tumors in rats is supported by a number of observations from both in vitro and in vivo studies. The knowledge that activated inflammatory cells can mediate a mutagenic response via released oxidants dates back to in vitro studies with human leukocytes and monocytes inducing bacterial mutations and modifications of DNA bases [reviewed by Weitzman and Gordon (21)]. First evidence supporting the inflammatory mechanism of particle-induced genotoxicity was provided by Driscoll (14) in ex vivo studies that showed that inflammatory cells obtained from the lungs of α-quartz-exposed rats are mutagenic to

![Figure 3](image-url)
Figure 4. Correlation between alveolar inflammatory response, determined by the appearance of neutrophils in bronchoalveolar lavage and alveolar epithelial cell mutation rates in rats dosed with various particle types (23), supporting the hypothesis of inflammation-induced mutagenesis. BAL, bronchoalveolar lavage.
INHALED PARTICLES AND THE MAXIMUM TOLERATED DOSE

inhalation studies the MTD concept that no significant toxicity unrelated to carcinogenicity should occur.

Use of the MTD as the highest dose (exposure level) in a chronic rodent bioassay assures that the animals are sufficiently challenged in order to identify agents that may be carcinogenic to humans, and also to identify potentially weak carcinogens. This means that hazard identification rather than risk characterization is the primary concern. Applying the concept of the MTD also provides the possibility to rank the carcinogenic potency of different compounds by comparing results from one study to another (36). The overall objective to maximize the likelihood of detecting a rodent carcinogen, and by implication a possible human carcinogen, when screening chemicals for their carcinogenic potential was the driving force for the MTD concept (37). The National Toxicology Program (NTP) prefers to refer to MTD as the minimally toxic dose (35) to avoid the misunderstanding that doses used are so excessive that animals barely survive. To decide whether the MTD has been achieved, major emphasis is placed on the histopathological evaluation of the target tissue. NTP (38) stated that at the MTD there should be no morphological evidence of toxicity that interferes with study interpretation. Increasingly, the process of dose selection is based on a mechanistic understanding of carcinogenesis. This is particularly important for agents like inhaled insoluble particles which, unlike soluble potentially reactive chemicals, are not metabolized in the lung but can be persistently retained, causing carcinogenicity secondary to toxicity as discussed previously. Thus, the selection of MTD for both fibrous and nonfibrous particles needs to include additional criteria to define the appropriate highest exposure concentration.

A recent U.S. Environmental Protection Agency (U.S. EPA)-sponsored workshop (39) titled "Chronic Inhalation Toxicity and Carcinogenicity Testing of Respirable Fibrous Particles" focused among other issues on the criteria for selecting the MTD for a chronic 2-year inhalation study to test carcinogenicity of fibers. In agreement with previous recommendations, it was suggested as a first step that the MTD for the chronic study should be based on the results of a subchronic multidose inhalation study with the fiber in question. This subchronic 3-month inhalation study, preferentially in rats, should show significant target organ responses at the highest exposure concentration to demonstrate that adequate dosing has been achieved. Rather than suggesting a highest exposure concentration in terms of number of fibers/cm³, the workshop participants recommended that changes in the following parameters in response to fiber exposure be used for estimating the MTD:

- Lung weight
- Bronchoalveolar lavage parameters—cellular and biochemical
- Lung fiber burden normalized to the exposure concentration, with special consideration of fibers longer than 20 μm
- Quantification of target cell proliferation.
- Alveolar macrophage-mediated particle clearance
- Histopathology

Participants also recommended that these end points not be considered individually, but should be evaluated in the context of changes observed with the other parameters to evaluate thoroughly all effects occurring at the highest dose level. A further recommendation was to determine fiber biopersistence as this is an important characteristic for adverse long-term effects of fibers. The focus of the MTD discussion was on target organ responses. It should be noted that body weight as an indication for achieving the MTD was not included in the above list by the workshop participants, although this end point was an important one for the original MTD definition as mentioned before. Likewise, mortality was not included for evaluating the MTD, as a subchronic 3-month inhalation study with particles is unlikely to result in increased mortality, and if so, other signs of toxicity would be highly obvious.

Although this workshop was devoted to the evaluation of fibrous particles, the same end points for assessing that the MTD has been achieved can also be used for nonfibrous particles. The obvious difference will be a higher dose deposited in the lung if the nonfibrous particles are of a rather benign type such as TiO₂ or carbon black. However, the lung dose can also be low for cytotoxic nonfibrous particles such as crystalline silica. To obtain information on the persistence of specific end points, investigators should evaluate these end points again after a postexposure recovery period of 3 months. This will provide valuable information, especially if comparisons are made to fibrous or nonfibrous particles that serve as reference material (such as asbestos or crystalline silica), where changes will be very persistent.

Several difficulties arise when applying these recommendations for conducting a study. One problem is that the MTD to be used in the 2-year chronic study is determined from a 3-month subchronic study. Minimal changes in toxicity occurring at the 3-month time-point may well develop further so that by the end of a chronic study the MTD has been exceeded by far. Even the second dose level which may not lead to significant responses by 3 months may do so at the end of a 2-year study. Moreover, no recommendations were made as to the degree of a response for the above-listed specific end points. Thus, a major open question still is what is an acceptable response which would unequivocally be accepted as reflecting the MTD? Or, in other words, how much of a target organ response is enough?

Only a few attempts have been made to address this question. Guidelines for carcinogenicity testing (40) recognize the problem of defining the MTD for chronic cancer bioassays, but are not very specific with respect to quantifying responses. Bucher et al. (35) characterized acceptable and unacceptable histopathological lesions for different target organs (liver, kidney, lung) for identifying an MTD. In general, acceptable responses in the target organ signifying that the MTD has been achieved include minimal/mild changes, whereas exceeding the MTD and unacceptable changes include necrosis and more severe pathological lesions. Specifically for the lung, suggested acceptable changes should be minimal in terms of histiocytosis, focal inflammation, fibrosis, and hyperplasia. Although no unacceptable responses specific to the lung were given by Bucher et al. (35), it can be assumed that greater than minimal changes would fall into this category. However, as pointed out by McConnell (36), histopathology is a subjective science and, therefore, defining the degree of a change is a major problem: "One pathologist may interpret a given change as being moderate in severity, while another would interpret the lesion as mild in nature." Thus, it could be extremely difficult to agree not only on the magnitude of a pathological change but also on what degree of change is necessary to characterize a specific exposure as having reached the MTD. Ideally, an objective method is needed to quantify and calibrate specific end points which could be generally agreed on as reflecting the MTD.
Another difficulty previously mentioned is whether a subchronic study (13 weeks) is sufficient to estimate the MTD for a chronic study. Figure 5 shows the results of a 2-year inhalation study in rats exposed to diesel exhaust at three different concentrations (41). Bronchoalveolar lavages and evaluation of cellular and biochemical parameters were performed at 6, 12, and 24 months of exposure. As Figure 5 shows, there is a significant shift in the shape of the exposure–response (inflammatory response determined by neutrophils in lung lavage) relationship over time. The mid-concentration of 3.5 mg/m³ showed only a slight increase in lavaged neutrophils of approximately 10% at 6 months of exposure, which is probably not indicative of an MTD being reached. However, at 12 months of exposure, lavaged neutrophils from rats of this exposure group had increased to 40%, which would likely be indicative of the MTD being reached or even exceeded; the neutrophil count in this group was even higher at 24 months of exposure. Only animals exposed to the mid and high concentrations in this particular study had increased lung tumor incidence (42), a result associated with a state of lung particle overload. Only the lowest concentration failed to induce lung tumors in the exposed rats, but even this concentration at the 24-month time point showed significant elevation of lavaged neutrophils (-27%). A subchronic 3-month study likely would not have given an indication that an MTD had been achieved based on the results of lavage analysis. Other end points mentioned above obviously would also need to be examined; however, the difficulty of using a 3-month study for predicting the MTD for the chronic study is quite obvious from this example.

At present, no appropriate user friendly definition of MTD for particle inhalation studies is available. One problem relates to the fact that we do not know whether the mechanisms that lead to lung tumors in rats after inhalation of particles are also operating in humans. However, the knowledge that some particulate compounds are known to be human carcinogens and are also known to have induced lung tumors in long-term rat inhalation studies could be used to characterize the MTD, and to validate and even quantify the specific end points listed previously so that they can be used for future studies with unknown particulate compounds.

**Defining the MTD for Particle Inhalation Studies**

Numerous chronic rat inhalation studies with fibrous and nonfibrous particles have been and are still performed with highest exposure concentrations assumed to be at the MTD. This assumption is based on an evaluation of changes in the target organ including several of the noncarcinogenic parameters suggested in the previous section, i.e., histopathology, particle dosimetry, lung weight, bronchoalveolar lavage parameters, and also the function of AM-mediated particle clearance. Significant changes in these parameters are taken as an indication of the MTD. Although this is consistent with suggestions made by scientists from regulatory agencies, academia, and industry, it is still disputed as to whether in a given case the MTD has been achieved despite significant changes in the target organ. One problem is a lack of exposure–dose–response information for changes in these noncarcinogenic end points that can occur in rats after subchronic/chronic exposure to a known human particulate carcinogen.

To establish an appropriate definition of the MTD for particle inhalation studies and to calibrate specific non-cancer end points to be used for this purpose, we suggest performing a chronic multidose rat inhalation study with a known human particulate carcinogen. With respect to fibrous particles, asbestos would be a good choice, possibly using a long form of amosite as has been used in a recent chronic hamster inhalation study (43). With respect to a non-fibrous particle, crystalline silica would be an appropriate choice as it has just recently been labeled a human carcinogen based on sufficient evidence of carcinogenicity from epidemiology of occupationally exposed workers (5). Both amosite and crystalline silica have been shown in long-term rat inhalation studies to induce tumors in this species (44–47). However, none of these previous long-term inhalation studies was concerned with the concept of MTD, no prechronic studies were performed, nor were specific non-cancer end points other than histopathology evaluated at the end of the 2-year time point. A characterization of specific pulmonary responses at different time points during a chronic study would therefore be needed to determine the degree of change in noncancer end points, which would indicate that an MTD was reached. If in the chronic study the known human particulate carcinogens induce lung tumors in the rat not only above but also below the MTD, this would confirm the validity of the underlying concept.

The suggested chronic study with long amosite or with crystalline silica could be designed as follows: Three or four concentrations of the particulate compounds should be used to expose male and female rats. Concentrations should range from approximately 10 to 200 fibers/cm³ for the amosite, and it should be assured that enough of the long fibers greater than 20 μm are present (-20%). For the crystalline silica, concentrations may range from 0.1 to 3 mg/m³, and the samples should consist of rat respirable particles. At 13 weeks of exposure, sufficient numbers of animals should be removed from the study so responses can be quantified regarding changes in lung weight, bronchoalveolar lavage parameters, lung burden of fibrous, and nonfibrous particles, alveolar–epithelial cell proliferation, AM-mediated particle clearance, and histopathology. Additional evaluations of the same end points may be performed at 6, 12, and 24 months of exposure. At the end of the 2-year study, the exposure–dose–response with respect to lung tumors and respective correlations to the noncancer end points measured during the study can be evaluated.

This is only a brief outline of the study; details still need to be worked out. Table 2 summarizes potential results in such study. It is assumed that at the end of the 2-year study a dose-dependent excess lung tumor incidence is observed so that the highest dose level satisfies the requirement of the MTD being reached or slightly exceeded. Toxicologically significant changes in noncancer end points at 3 months of exposure are assumed to be dose dependent, and three possible scenarios are listed in Table 2. Scenario 1 shows significant changes in noncancer end points only at the highest dose.
INHALED PARTICLES AND THE MAXIMUM TOLERATED DOSE

Table 2. Testing for pulmonary carcinogenicity of inhaled fibrous and non-fibrous particles in rats: principles of establishing an MTD benchmark by quantifying non-cancer end points (see text) in a multidose inhalation study with the known human particulate lung carcinogens amosite or crystalline SiO2. Scenario 1 is the ideal outcome and would validate the present MTD concept.

| Inhaled particulate concentration | Low | Mid | High |
|----------------------------------|-----|-----|------|
| Excess tumors at end of 2-year study | –   | +   | ++ (+> MTD) |
| Toxicologically significant changes in non-cancer end points at 3 months of exposure | Scenario 1 | –   | –   | +   |
|                                   | Scenario 2 | –   | +   | ++  |
|                                   | Scenario 3 | +   | ++  | +++ |

In scenario 2 such changes are assumed to occur only in those groups in which tumors are seen, whereas in scenario 3 respective changes are assumed to be induced even at the lowest level where no tumors are seen. Only in scenario 1 did tumors occur below the MTD. Respective changes for the non-cancer end points can thus be quantitated (e.g., x-fold increase of neutrophils in lung lavage, or in target cell proliferation, etc.). The quantification of these changes at the 3-month time point could then be used as a benchmark for future studies with other non-fibrous and fibrous particles in a subchronic study designed to determine the MTD for a subsequent chronic study. This outcome of scenario 1 would validate the MTD concept with known human particulate carcinogens for the chronic rat bioassay.

If, however, amosite or crystalline silica induce only lung tumors in those groups that show significant changes in the non-cancer end points at 3 months and at later time points (scenario 2) or non-cancer changes occur even without excess tumors (Scenario 3), then we may have to reconsider the concept of MTD for particle inhalation studies. The implication of such findings would be either that mechanisms of amosite/silica-induced lung tumors between rats and humans are very different, or that humans in the positive epidemiologic studies were exposed at or above the human MTD. In the first case, the use of the rat as a model in cancer bioassays for inhaled particles needs to be reevaluated—the rat may have to be characterized as inappropriate for this purpose. In the second case, the MTD principle may need to be extended to include dose levels above the MTD in a rat-cancer bioassay with particles (scenarios 2 and 3 in Table 2). For example, the degree of an acceptable inflammatory or other toxic response may have to be greater than minimal as suggested by the present MTD concept.

Concluding Remarks

Assuming that the MTD concept has been validated by the studies outlined in the previous section and using the calibrated noncancer end points previously suggested, the carcinogenic potential of new particulate materials can be evaluated in a chronic cancer inhalation bioassay in the rat. If, however, regulators need to determine how to classify a particulate compound if a tumor response occurs only at and above MTD levels. Should such a compound be characterized as a possible human carcinogen? The U.S. EPA, when removing TiO2 from its toxic substances inventory (8), used the weight of evidence approach to determine that lung tumors induced in rats at high levels of TiO2 were secondary to toxicity, based on lung particle overload. Thus, it becomes important in such cases to evaluate mechanisms of lung toxicity and carcinogenicity for fibrous and nonfibrous particles, specifically comparing low versus high doses.

For an evaluation of secondary mechanisms such as inflammation-induced carcinogenesis (Figure 3), quantification of the specific end points of toxicity would also be very helpful. For example, the magnitude of an increase in inflammatory neutrophils in bronchoalveolar lavage and its significance for inducing mutational events in target cells may depend highly on the level of anti-inflammatory and antioxidant defenses. It may be possible to define an acceptable increase in lung lavage neutrophils (e.g., 20 or 30% of the lavaged cell population), which, although significant, may not be viewed as being above the MTD; i.e., levels of significance for toxic responses could be redefined.

It should be considered that for an evaluation of these noncancer end points only a small number of animals (~5) is necessary, whereas a carcinogenic effects study requires much greater numbers (50-100 per group) in order to detect significant tumorigenicity even at high doses. The definition of a high dose is by convention based on the gravimetric dose but should be redefined and based on the observed changes in non-cancer end points. For example, in the case of particles that have a strong inflammatory and fibrogenic potency, e.g., crystalline SiO2, the markers of inflammation will be present at much lower mass doses than with TiO2. However, at equal degrees of a chronic inflammatory response (above MTD), the lung tumor response in rats may well be the same for low dose SiO2 and high dose TiO2. What we do not know and what needs to be determined is whether the confirmed human carcinogen crystalline SiO2 also induces lung tumors in rats at or below dose levels defined as the MTD in a validation study that is designed as suggested in this paper. If tumors are not induced at lower levels, the concept of the MTD for particle inhalation studies has to be reconsidered.

Being able to define the MTD based on the outcome of a validated study is obviously important for the long-term cancer bioassay. However, such long-term inhalation studies with particles are very time- and cost-consuming, and one future goal would be to develop short-term assays that will allow us to determine the carcinogenic potential of an unknown particulate compound. With respect to fibers, one approach presently being discussed involves combining in a short-term assay the evaluation of the biodurability of an unknown fiber with evaluation of specific end points of toxicity after an inhalation exposure as short as 5 days with subsequent sufficient time for observation. This short-term assay for fibers is based on the rationale that a fiber that is dissolved within a short period of time in the lung will no longer be fibrogenic or carcinogenic. The concept of biodurability for long-term chronic effects is also principally applicable to nonfibrous particles, e.g., crystalline silica (poorly soluble) versus amorphous silica (soluble in the lung). However, for the development of short-term assays, more research is still needed to gain insight into the mechanisms of particle-induced lung tumors so that future assays, either in vivo or in vitro, can be based on a better knowledge of cellular/molecular events.

Another important research area to be addressed in future studies is the significant species difference in response between rats on the one hand and mice and hamsters on the other. Why are mice and hamsters less susceptible to pulmonary inflammation, fibrosis, and carcinogenicity? With respect to the inflammatory mechanisms of lung tumor induction, a number of questions could be answered by evaluating species differences in the recruitment of neutrophils to the lung and their state of activation; investigating the
mutagenic potential of activated neutrophils from mice and hamsters to epithelial target cells; or determining the response of lung epithelial cells from mice and hamsters to mutagenic stimuli in comparison to rat epithelial cells. To answer these and other related questions would give important insight into reasons for the apparent resistance of some rodent species to lung tumor induction by particles. Finally, a significant gap in our knowledge needs to be closed by comparing rodent and human responses using lung cells from these species for evaluation of cellular and molecular events. The hope is that mechanistic knowledge gained from these studies will in the future permit us to replace the long-term cancer bioassay with acceptable short-term assays.

REFERENCES

1. Sontag JM, Page NP, Saffiotti U. Guidelines for Carcinogen Bioassay in Small Rodents. DHHS Publ (NIH) 76-801, Bethesda, MD:National Institutes of Health, 1976.

2. Lee KP, Trochimowicz HJ, Reinhardt CF. Pulmonary response of rats exposed to titanium dioxide (TiO2) by inhalation for two years. Toxicol Appl Pharmacol 79:179–192 (1985).

3. Heinrich U, Fuhrst R, Rittinghausen S, Creutzenberg O, Bellmann B, Koch W, Levens K. Chronic inhalation exposure of Wistar rats and two different strains of mice to diesel engine exhaust, carbon black, and titanium dioxide. Inhal Toxicol 7:533–556 (1995).

4. ACIGIH. American Conference of Governmental Industrial Hygienists: 1993-1994. Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices. Cincinnati, OH:ACIGIH, 1996.

5. IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 68: Silica, Some Silicates, Coal Dust and para-Aramid Fibers. Lyon:International Agency for Research on Cancer, 1997.

6. Morrow PE. Possible mechanisms to explain dust overloading of the lungs. Fundam Appl Toxicol 10:369–384 (1988).

7. Oberdörster G. Lung particle overload: implications for occupational exposures to particles. Regul Toxicol Pharmacol 27:123–135 (1995).

8. U.S. EPA. Toxic chemicals release reporting: reporting community right-to-know; titanium dioxide. Fed Reg 53:23107–23202 (1988).

9. Stöber W, Embroutil HJ, Klosterkötter W. Quantitative studies of dust retention in animal and human lungs after chronic inhalation. In: Inhaled Particles and Vapours, II (Davies CN, ed). Oxford, UK:Pergaomon Press, 1965;409–418.

10. Martin JC, Daniel H, Le Bouffant L. Short- and long-term experimental study of the toxicity of coal-mine dust and of some of its constituents. In: Inhaled Particles, IV: Part I (Wallon WH, McGovern B, eds). Edinburgh:Pergamon Press, 1977;361–371.

11. Oberdörster G, Ferin J, Lethner BE. Correlation between particle size, in vivo particle persistence, and lung injury. Environ Health Perspect 102(Suppl 5):173–179 (1994).

12. Oberdörster G, Ferin J, Soderholm S, Gelein R, Cox C, Baggs R, Morrow PE. Increased pulmonary toxicity of inhaled ultrafine particles: due to lung overload alone? Ann Occup Hyg 38(Suppl 1):295–302 (1994).

13. Oberdörster G, Yu CP. The carcinogenic potential of inhaled diesel exhaust: a particle effect? J Aerosol Science 21(S1):S397–S401 (1990).

14. Driscoll KE. The role of inflammation in the development of rat lung tumors in response to chronic particle exposure. Inhal Toxicol 8(Suppl):139–155 (1996).

15. Seixas NS, Hewett P, Robins TG, Haney R. Variability of particle size-specific fractions of personal coal mine dust exposures. Am Ind Hyg Assoc J 56:243–250 (1995).

16. Burkhart JE, McCawley MA, Wheeler RW. Particle size distributions in underground coal mines. Am Ind Hyg Assoc J 48(2):122–126 (1987).

17. McConnell EE, Mast RW, Hesterberg TW, Chevalier J, Kotin P, Bernstein DM, Thévenaz P, Glass L, Anderson R. Chronic inhalation toxicity of a kaolin-based refractory ceramic fiber in Syrian golden hamsters. Inhal Toxicol 7:503–532 (1995).

18. Borellka BE, Sestini P, Gaumer HR, Hammad Y, Heather CJ, Salvaggio JE. A murine model of asbestosis. Am J Pathol 112:326–337 (1983).

19. Driscoll KE, Hassenbein DG, Carter J, Poynter, J, Asquith TN, Grant RA, Whittem J, Purdon MP, Takiguki R. Macrophage inflammatory proteins 1 and 2: expression by rat alveolar macrophages, fibroblasts, and epithelial cells and in rat lung after mineral dust exposure. Am J Respir Cell Mol Biol 8:311–318 (1993).

20. Cross CE, Eiserich JP, Halliwell B. General biological consequences of inhaled environmental toxicants. In: The Lung: Scientific Foundations. Vol 2. 2nd ed (Crystal RG, West JB, Weibel ER, Barnes PJ, eds). Philadelphia:Lippincott-Raven, 1997;2421–2437.

21. Weitzman, SA, Gordon LL. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 76(4):655–663 (1990).

22. Driscoll KE, Carter JM, Howard BW, Hassenbein DG, Pedelko W, Baggs RB, Oberdörster G. Pulmonary inflammatory, chemokine, and mutagenic responses in rats after subchronic inhalation of carbon black. Toxicol Appl Pharmacol 136:372–380 (1996).

23. Driscoll KE, Deyo LC, Carter JM, Howard BW, Hassenbein D, Bertram TA. Effects of particle exposure and exposure to particle-elicited inflammatory cells on mutation in rat alveolar epithelial cells. Carcinogenesis 18:423–439 (1997).

24. Henderson R, Mauderly J, Pickrell J, Hahn F, Muhle H, Rebar A. Comparative study of bronchoalveolar lavage fluid: effect of species, age and method of lavage. Exp Lung Res 13:329–342 (1987).

25. Slade R, Stead AG, Graham JA, Hatch GE. Comparison of lung antioxidant levels in humans and laboratory animals. Am Rev Respir Dis 131:742–746 (1985).

26. Buckpitt A, Chang A-M, Wei A, Van Winkle L, Duan X, Philpot R, Plopper C. Relationship of cytochrome P450 activity to Clara cell cytotoxicity. IV: Metabolism of naphthalene and naphthalene oxide in microdissected airways from mice, rats, and hamsters. Mol Pharmacol 47:74–81 (1995).

27. Carlsson LM, Marklund SL, Edlund T. The rat extracellular superoxide dismutase dimer is converted to a tetramer by the exchange of a single amino acid. Proc Natl Acad Sciences USA 93(11):5219–5222 (1996).

28. Huax F, Hudspith B, Meredith C, Lison D. Unpublished data.

29. Carter JM, Howard BW, Driscoll KE. Unpublished data.

30. Heinrich U, Muhle H, Takenaka S, Ernst H, Fuhrst R, Mohr U, Port F, Stöber W. Chronic effects on the respiratory tract of hamsters, mice and rats after long-term inhalation of high concentrations of filtered and unfiltered diesel engine emissions. J Appl Toxicol 6:383–395 (1986).

31. Saffiotti U, Stinson SF. Lung cancer induction by crystalline silica: relationship to granulomatous reactions and host factors. Environ Carcinog Rev C6:97–222 (1988).

32. Muhle H, Creutzenberg O, Bellmann B, Heinrich U, Mermelstein R. Dust overloading of lungs: investigations of various materials, species differences, and irreversibility of effects. J Aerosol Med 3(Suppl 1):S11–S128 (1990).

1354 Environmental Health Perspectives • Vol 105, Supplement 5 • September 1997
33. NTP. Toxicology and Carcinogenesis Studies of Talc in F344/N Rats and B6C3Fl Mice. Technical Rept Ser No 421. NIH Publ 93–3152. Research Triangle Park, NC:National Toxicology Program, 1993.

34. Maronpot RR, Fox T, Malarkey DE, Goldsworth TL. Mutations in the rat proto-oncogene: clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology 101: 125–156 (1995).

35. Bucher JR, Portier CJ, Goodman JJ, Faustman EM, Lucier GW. Workshop overview—National Toxicology Program Studies: Principles of Dose Selection and Applications to Mechanistic Based Risk Assessment. Fundam Appl Toxicol 31:1–8 (1996).

36. McConnell EE. Maximum tolerated dose in particulate inhalation studies: a pathologist's point of view. Inhal Toxicol 8 (Suppl):111–123 (1996).

37. Morrow PE, Haeman JK, Hobbs CH, Driscoll KE, Vu V, Oberdorster G. Workshop Overview: The Maximum Tolerated Dose for Inhalation Bioassays: Toxicity vs. Overload. Fundam Appl Toxicol 29:155–167 (1996).

38. NTP. Report of the NTP Ad Hoc Panel on Chemical Carcinogenesis Testing and Evaluation. Research Triangle Park, NC:National Toxicology Program, 1984.

39. U.S. EPA. Workshop Report on Chronic Inhalation Toxicity and Carcinogenicity Testing of Respirable Fibrous Particles. EPA-748-R-96-001. Washington:U.S. Environmental Protection Agency, 1996.

40. U.S. EPA. Proposed Guidelines for Cancer Risk Assessment. Fed Reg 61:17960 (1996).

41. Henderson RF, Pickrell JA, Jones RK, Sun J, Benson J, Mauderly JL, McClellan RO. Response of rodents to inhaled diluted diesel exhaust: biochemical and cytological changes in bronchoalveolar lavage fluid and in lung tissue. Fundam Appl Toxicol 11:546–567 (1988).

42. Mauderly JL, Jones RK, Griffith WC, Henderson RF, McClellan RO. Diesel exhaust is a pulmonary carcinogen in rats exposed chronically by inhalation. Fundam Appl Toxicol 9:208–221 (1987).

43. Hesterberg TW, Axten C, McConnell EE, Oberdörster G, Everitt J, Müller WC, Chevalier J, Chase GR, Thévenaz P. Chronic inhalation study of fiber glass and amosite asbestos in hamsters: twelve month preliminary results. Environ Health Perspect 105(Suppl 5):1223–1229 (1997).

44. Muhle H, Takenaka S, Mohr U, Dasenbrock C, Mermelstein R. Lung tumor induction upon long-term low-level inhalation of crystalline silica. Am J Ind Med 15: 343–346 (1989).

45. Davis JMG, Addison J, Bolton RE, Donaldson K, Jones A, Smith T. The pathogenicity of long versus. short fibre samples of amosite asbestos administered to rats by inhalation and intraperitoneal injection. Br J Exp Pathol 67:415–430 (1986).

46. Davis JMG, Jones AD, Miller BG. Experimental studies in rats on the effects of asbestos inhalation coupled with the inhalation of titanium dioxide or quartz. Int J Exp Pathol 72:501–525 (1991).

47. Wagner, JC, Berry, G, Skidmore JW, Timbrell V. The effects of the inhalation of asbestos in rats. Br J Can 29:252–269 (1974).